Iaso Biopharma Presents Clinical Data of Equecabtagene Autoleucel in Central Nervous System Autoimmune Diseases at EAN 2024

Jul 02, 2024 08:42 CST Updated 08:42

IASO Biotechnology

Cancer Treatment New Drug Developer

On July 1, 2024, IASO Bio, a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative cell therapies, delivered an oral presentation at the 2024 European Academy of Neurology (EAN) Annual Meeting.Clinical Data and Single-Cell Multi-Omics Analysis of IASO Bio's Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Equecabtagene Autoleucel) for the Treatment of Central Nervous System Autoimmune Diseases。

Professor Qin Chuan from Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOral Presentation at the EAN Annual Meeting

This report is based on the results of an investigator-initiated exploratory clinical study (NCT04561557) evaluating the safety and efficacy of infusing Icaritin Cell Injection for the treatment of relapsed/refractory antibody-mediated idiopathic inflammatory neurological diseases. The study is being conducted at Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, by a research team led by Professor Wei Wang from the Department of Neurology at Tongji Hospital.

The study enrolled 12 subjects with aquaporin-4 (AQP4) antibody-positive relapsing/refractory neuromyelitis optica spectrum disorder (NMOSD). The enrolled subjects were patients who had been treated with at least one immunosuppressant for more than a year but had poor symptom control. The results showed that the Icarus injection demonstrated good tolerability and safety, persistent clearance of pathogenic antibodies, and potential clinical efficacy in NMOSD. CAR-T cells with chemotactic properties can penetrate the blood-brain barrier into the central nervous system, directly killing abnormal plasma cells, reducing intrathecal autoantibody secretion and abnormal immune cell activation, thereby correcting the immunological disorder in the central nervous system of NMOSD patients, which is beneficial for central immune reconstitution in patients.

Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and IASO Bio, as one of the world's first research teams to use BCMA CAR-T in treating immune disorders, have validated the clinical value of innovative cell therapy for relapsed and refractory immune diseases through their groundbreaking research achievements. This has increasingly gained recognition and attention globally. Currently,BCMA CAR-T therapy has been evaluated by the International Neuromyelitis Optica Study Group (NEMOS) as one of the most promising treatment strategies and included in the latest revised treatment recommendations (J Neurol 2024).Maximilian F. Konig, a professor in the Department of Immunology at Johns Hopkins University, pointed out in his Year in Review article for *Nat Rev Rheumatol* ("Immunotherapies in 2023: The Rise of Precision Cellular Therapies") that,The application of CAR-T therapy has brought about epoch-making progress in innovative cellular treatments for immunological diseases.。

The principal investigator of this clinical study, Professor Wang Wei from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology"This study is the world's first clinical trial of CAR-T therapy in the field of AQP4-mediated relapsing/refractory NMOSD, not only demonstrating the encouraging efficacy and controllable safety of Ixcellen injection in NMOSD but also elucidating the cellular kinetics and immunological characteristics of CAR-T therapy in treating central nervous system autoimmune diseases. It provides a new therapeutic approach for antibody-mediated autoimmune diseases and offers important scientific evidence for the iterative improvement of subsequent CAR-T cell therapy products for immune disorders. In addition to NMOSD, Ixcellen injection has shown excellent clinical efficacy in treating other antibody-mediated autoimmune diseases, including myasthenia gravis and immune-mediated necrotizing myopathy, even reversing disease symptoms, with multiple related research papers published in authoritative international academic journals. The patient population with autoimmune diseases is large, with recurrent episodes that are difficult to cure, requiring long-term or even lifelong medication, reflecting significant unmet clinical needs. We will continue to explore the application of Ixcellen injection in more refractory autoimmune diseases in collaboration with the IASO Bio team, aiming to transform the treatment landscape of autoimmune diseases."

”

About IASO Bio

IASO Bio is a biopharmaceutical company dedicated to the research, production, and sales of innovative cell-based drugs. With a focus on developing cellular therapies and antibody drugs for hematological malignancies as its innovation cornerstone, the company is expanding into autoimmune diseases, possessing comprehensive capabilities across the entire process from early discovery, clinical development, regulatory submission, to commercial-scale manufacturing.

The company currently has more than 10 innovative drug candidates at various stages of development. Among them, the injection of Ixazomib (a fully human BCMA CAR-T product) has been approved for marketing by the National Medical Products Administration (NMPA) in China and has also received approval from the U.S. FDA for registration in clinical trials to treat relapsed/refractory multiple myeloma.

IASO Bio, with its strong management team, innovative product pipeline, self-owned GMP manufacturing, and robust clinical development capabilities, aims to provide transformative and curative innovative therapies, bringing hope of a cure to patients in China and around the world.

E.N.D

Previous article recommendations:

Ten Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields

Over 10 billion yuan investment! Beijing introduces hard-core measures, multi-factor support for cell and gene therapy, artificial intelligence and other high-end industries

Yosemite Biosciences Announces the Appointment of Ms. Chen Lijuan as Interim CEO

A Gene Therapy Company in Hangzhou Officially Opens

Yukadi's Innovative Solid Tumor CAR-T Drug Approved for Clinical Trials

China's First Stem Cell New Drug Submits for Market Approval and Receives Priority Review

Chengdu Maikang Bio Completes C+ Round Financing, Company's Total Financing Exceeds 1 Billion

Investment of 650 million yuan, covering 33 mu, focusing on the cell and gene therapy industry, a GMP factory opens in Suzhou

Shocking Discovery! Nearly 50% of Lab-Made DIY Plasmids Have Significant Design Flaws and Sequence Errors

CDE Releases "Technical Guideline for Clinical Pharmacology Studies of Cell Therapy Products (Draft for Comments)"

CSPC's First mRNA-LNP-Based CAR-T Cell Injection Approved for Clinical Trials

Nanjing Airport Opens Import and Export Channel for CAR-T Cell Therapy Drugs

Belief BioMed Announces Long-Term Follow-Up Data of the First AAV Gene Therapy Clinical Study

China's First mRNA-LNP Technology Group Standard Draft for Comment, Involving Cell Therapy

Jitai Pharmaceutical Completes $100 Million Series C Financing, Focusing on "AI + Drug Delivery"

Official Signing! A Biomedical Innovation Company Settles in Minhang

Farewell to Insulin Injections: Cell Therapy VX-880 Shows Promising Results in Phase Ⅰ/Ⅱ Clinical Trials for Diabetes

Planned Investment of 210 Million Yuan: A Cell Drug Production Base in China to Begin Construction Soon

Priced at $3.2 Million, First DMD Gene Therapy Receives Full FDA Approval!

CDE: It is recommended to include cell and gene therapy products within the scope of advanced therapy medicinal products.

Manufacturing Process and Challenges of Universal CAR-T

Two Gene Therapy Companies Merge

Stock Price Surges 477%, CD20 CAR-T Cell Therapy Breaks Through Again

CARsgen Pharma Announces Latest Clinical Data for Two CAR-T Products

To Enhance Cell Therapy Drug Production Capacity, Gracell Biotechnologies Decides to Add 9,000 Square Meters of Manufacturing Facilities

First Case in China! Adult Hereditary Deafness Gene Therapy Successfully Performed at Xijing Hospital

Just now, the FDA released an industry guideline on the development of oligonucleotide drugs.

Clinical Research Ward of Xiamen Cell Therapy Research Center Officially Launched

Latest Breakthrough by Liu Rulian's Team! Efficient Insertion of Entire Genes, One Therapy for Hundreds or Thousands of Diseases Caused by Genetic Mutations

ChatGPT Founder Bets Over 1.2 Billion on New Track

Disclaimer: The graphic content is sourced from the company's official channels. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.